Annual Report to the Nation 2019: National Cancer Statistics https://t.co/WMlTqlXG87
12:04pm May 30th 2019 via Buffer
Cancer-fighting data company Tempus raises another $200 million, making it one of Chicago’s highest valued startups https://t.co/8OJkBZEk3i
11:04am May 30th 2019 via Buffer
Sysmex Inostics OncoBEAM-EGFR digital PCR liquid biopsy demonstrates two-fold higher detection of p.T790M mutations… https://t.co/AUyTiVf3ru
6:41am May 30th 2019 via Buffer
@AlbertVilella @jdidion Whoops - missed that! Thanks for pointing it out, profile corrected now.
8:19pm May 28th 2019 via Twitter Web Client in reply to AlbertVilella
@AlbertVilella @jdidion Hey Albert and John - yes only the fourth week in the new role, and lots and lots of things… https://t.co/OKaZyNxwr6
10:19am May 28th 2019 via Twitter Web Client in reply to AlbertVilella
If you didn't think you could trust an NGS clinical test for ctDNA below 1% MAF, take a look at this - from Sysmex… https://t.co/xIyLcM5kOS
10:02am May 28th 2019 via Twitter Web Client
If you didn't think you could trust an NGS clinical test for ctDNA below 1% MAF, take a look at this - from Sysmex… https://t.co/HIcat7Qvy7
7:25am May 28th 2019 via Twitter Web Client
Q: Number of droplets in the technology? Upper limit for GEC? Lipson: #oncobeam #genomewebinar Defers to Sysmex; c… https://t.co/p0Xk9JdQml
12:01pm May 8th 2019 via Twitter Web Client
Q: Hemolytic samples with BEAMing? Holdenrieder: #oncobeam #genomewebinar Preanalytics important; normal EDTA blood… https://t.co/6gCMHfF3Mx
11:58am May 8th 2019 via Twitter Web Client
Q: For clinical work? Lipson: #oncobeam #genomewebinar Impt - what is clinically important? BRAF in melanoma import… https://t.co/T7Q1PpTgKb
11:57am May 8th 2019 via Twitter Web Client
Q: How does BEAMing compare to ddPCR? Holdenrieder: #oncobeam #genomewebinar Different as quality, different as num… https://t.co/IymwZ4D8qc
11:55am May 8th 2019 via Twitter Web Client
Q: How many muts can be measured with the tech? Holdenrieder: #oncobeam #genomewebinar They tested for 5, for BRAF/NRAS measures 7.
11:53am May 8th 2019 via Twitter Web Client
Q: Do you thus incorporate ctDNA into practice? Lipson: #oncobeam #genomewebinar Useful in a few ways; standard, pt… https://t.co/0Ppm1d4WN7
11:52am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Important - what CNAPS structure, biology and function.
11:48am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Summarizing - KRAS correlation 'was good but could be better', KRAS prognost… https://t.co/d123xotaFY
Holdenrieder: #oncobeam #genomewebinar Early kinetics: after the first day of Rx, increased considerably. then sha… https://t.co/RPRBsJTS5S
11:46am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Shows chart of sens for det of progressive disease, ctDNA reached 83% in de… https://t.co/p06N32OpVx
11:44am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Found mut in tissue not prognostic, but mut in plasma was. Compared to 3 pr… https://t.co/Sg5oXsYLHK
11:41am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Total 32 muts found in tissue (58%), 36 in plasma. Very high concordance: 7… https://t.co/LjUnLBHy0N
11:40am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Did pyroseq for tissue, BEAMing with plasma. Shows typical results of measu… https://t.co/67xwIcmFBY
11:38am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Asks: do plasma and tissue correlate? Prognostic for pt outcome (OS and PFS… https://t.co/Ja8cY8uNmS
11:37am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar 54 pts with adv panc ca; first-line gemcitabine-based chemo. Tissue + Plasm… https://t.co/uOLcDz7s18
11:36am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Shows chart of freq of KRAS, tp53 mutations in panc cancer. Points to prosp… https://t.co/V3BUkK1SgV
11:35am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar In Pancreatic cancer - not as frequent but high mortality. Often detected l… https://t.co/NFwMgKF5VA
11:34am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar If the mut load is needed, you need to 'go quantitative'. Nice (long!) list… https://t.co/Kj5y37pvBS
11:33am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar BEAMing has high concordance - four references where concordance >90%. Indi… https://t.co/Hc6R315
11:32am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Shows Bettegowda et al figure of percent of cancer types that have detectab… https://t.co/8VfdiVxY1Y
11:31am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Describes liquid biopsy as 'liquid profiling' - as it is looking at markers… https://t.co/etr6P5HMJu
11:30am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Nice review of markers by tumor tpe, and description of tumor heterogeneity… https://t.co/BthwRQ4b7F
11:29am May 8th 2019 via Twitter Web Client
Stefan Holdenrieder (Technical University of Munich) OncoBEAM for ctDNA in monitoring of pancreatic cancer. Starts… https://t.co/5ViaGfin74
11:28am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Concl: ctDNA useful melanoma biomarker.
11:27am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Shows example of 68yo female on pembro for met melanoma baseline 0.95% ctDNA, 1.5c… https://t.co/y2Np7TZ9Cr
11:25am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Shows timeline of EDA in circulation prior to imaging in 4 pts. Ave 24 weeks before detection via imaging.
11:23am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar 4/8 pts PD coincident of EDA in ctDNA; other 4 predicted radiographic progression… https://t.co/t3c5PPGzjt
11:22am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Cohort C: n=36, 30 evaluable. All treated, charted mut status, collected serial ct… https://t.co/ff5rHYotd4
11:21am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Cohort B: n=31, 29 evaluable. Recurrent w/1 of 6 hotspot muts: Locoregoinal spread… https://t.co/XJH3Wt46cs
11:19am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Cohort A concl: of 57 pt, 35mm ideal cutoff, two pts unmeasured BRAF in tissue but… https://t.co/0aL0C7YA6M
11:17am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar One pt no BRAF mut in tissue; another insuff quality: both ctDNA revealed bRAF; bo… https://t.co/0xQR3XTtOE
11:16am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Shows burden of 9 pts w/smaller tumors and location - visceral, lung etc. Chart fr… https://t.co/g9gjv4LeIP
11:15am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Of the five + in tumor but neg in ctDNA: low tumor burden (small size). ROC of coh… https://t.co/qFKaeGoUno
11:14am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar 61 pts of cohort A: BRAF 26; NRAS 11; WT 20; N/A: 4. Shows chart of 32/33 pos in… https://t.co/JbAnzxoRlb
11:13am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar 3 cohorts: A single blood draw of met melanoma; B high-risk resected melanoma, ser… https://t.co/f9FdihHLh2
11:11am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Aims - est concordance, est clinical LoD. Single-center study at Hopkins; looked a… https://t.co/M4zAOCArOp
11:10am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Also shows pt after tumor needle biopsy, shows ctDNA level spiking after the biops… https://t.co/UJ6ioysdNt
11:08am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Shows increasing levels of ctDNA correlate w/radiographic disease progression. GEC… https://t.co/M3yOpHOAfS
11:06am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Only two mutations (BRAF and NRAS) represent 50% and 30% of recurrence in melanoma… https://t.co/yW2LQvHRkL
11:05am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Starts with a patient stroy - primary, regional recurrence, and distant mets. LDH… https://t.co/4KrjgVxcyo
11:04am May 8th 2019 via Twitter Web Client
Evan Lipson (Johns Hopkins Kimmel CC) Liquid monitoring - optimizing melanoma detection using ctDNA #oncobeam #genomewebinar
11:02am May 8th 2019 via Twitter Web Client
Evan Lipson (Johns Hopkins Kimmel CC) and Stefan Holdenrieder (Technical University of Munich) presenting an… https://t.co/Kui6oM2MKx
11:00am May 8th 2019 via Twitter Web Client
Live Webinar Wed May 8 11am ET OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Mel… https://t.co/CwXVUjZmuq
10:39am May 8th 2019 via Twitter Web Client
